A new drug regimen combining PARP inhibitors and deoxyuridine agents, i.e., TAS102 or FdUrd, expands the clinical utility of these therapeutic agents to p53-mutant cancers that account for the majority of TNBC and nearly half of all BC cases. Here, TP53 is linked to breast cancer.